Collegium Pharmaceutical, Inc. COLL Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| Belbuca | $52.65M-11.0% | $59.14M+1.5% | $58.26M+10.8% | $52.6M+1.8% | $51.66M-6.4% | |
| Jornay PM | $38.89M-15.2% | $45.89M+9.8% | $41.8M+28.1% | $32.63M+14.3% | $28.54M-2.5% | |
| Nucynta ER AG | $1.45M— | —— | —— | —— | $0— | |
| Nucynta ER | $18.23M-1.7% | $18.54M-18.7% | $22.81M+14.4% | $19.95M+1.3% | $19.69M+12.3% | |
| Nucynta IR AG | $1.26M— | —— | —— | —— | $0— | |
| Nucynta IR | $26.08M-11.3% | $29.41M-8.1% | $31.99M+20.7% | $26.5M-3.3% | $27.42M+13.2% | |
| Symproic | $4.19M— | —— | $4.03M+8.1% | $3.72M+32.2% | $2.82M-33.8% | |
| Xtampza ER | $50.77M— | —— | —— | —— | $47.64M-0.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Collegium Pharmaceutical, Inc. break its business down?
- Collegium Pharmaceutical, Inc. (COLL) reports product revenues, net by product across 9 parts — Belbuca, Jornay PM, Nucynta ER AG, Nucynta ER and Nucynta IR AG. Each is extracted from the segment footnotes and tracked over time.
- Where does Collegium Pharmaceutical, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Collegium Pharmaceutical, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
